Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

PHOSPHO1 is essential for normal bone fracture healing: An Animal Study.

Morcos MW, Al-Jallad H, Li J, Farquharson C, Millán JL, Hamdy RC, Murshed M.

Bone Joint Res. 2018 Jul 7;7(6):397-405. doi: 10.1302/2046-3758.76.BJR-2017-0140.R2. eCollection 2018 Jun.

2.

Osteogenesis Imperfecta Type VI in Individuals from Northern Canada.

Ward L, Bardai G, Moffatt P, Al-Jallad H, Trejo P, Glorieux FH, Rauch F.

Calcif Tissue Int. 2016 Jun;98(6):566-72. doi: 10.1007/s00223-016-0110-1. Epub 2016 Jan 27.

PMID:
26815784
3.

Comprehensive Review of Adipose Stem Cells and Their Implication in Distraction Osteogenesis and Bone Regeneration.

Morcos MW, Al-Jallad H, Hamdy R.

Biomed Res Int. 2015;2015:842975. doi: 10.1155/2015/842975. Epub 2015 Sep 13. Review.

4.

Recessive osteogenesis imperfecta caused by missense mutations in SPARC.

Mendoza-Londono R, Fahiminiya S, Majewski J; Care4Rare Canada Consortium, Tétreault M, Nadaf J, Kannu P, Sochett E, Howard A, Stimec J, Dupuis L, Roschger P, Klaushofer K, Palomo T, Ouellet J, Al-Jallad H, Mort JS, Moffatt P, Boudko S, Bächinger HP, Rauch F.

Am J Hum Genet. 2015 Jun 4;96(6):979-85. doi: 10.1016/j.ajhg.2015.04.021. Epub 2015 May 28.

5.

The effect of SERPINF1 in-frame mutations in osteogenesis imperfecta type VI.

Al-Jallad H, Palomo T, Roughley P, Glorieux FH, McKee MD, Moffatt P, Rauch F.

Bone. 2015 Jul;76:115-20. doi: 10.1016/j.bone.2015.04.008. Epub 2015 Apr 11.

PMID:
25868797
6.

A polyadenylation site variant causes transcript-specific BMP1 deficiency and frequent fractures in children.

Fahiminiya S, Al-Jallad H, Majewski J, Palomo T, Moffatt P, Roschger P, Klaushofer K, Glorieux FH, Rauch F.

Hum Mol Genet. 2015 Jan 15;24(2):516-24. doi: 10.1093/hmg/ddu471. Epub 2014 Sep 11.

PMID:
25214535
7.

Normal bone density and fat mass in heterozygous SERPINF1 mutation carriers.

Al-Jallad H, Palomo T, Moffatt P, Roughley P, Glorieux FH, Rauch F.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2446-50. doi: 10.1210/jc.2014-2505. Epub 2014 Aug 15.

PMID:
25127091
8.

Skeletal characteristics associated with homozygous and heterozygous WNT1 mutations.

Palomo T, Al-Jallad H, Moffatt P, Glorieux FH, Lentle B, Roschger P, Klaushofer K, Rauch F.

Bone. 2014 Oct;67:63-70. doi: 10.1016/j.bone.2014.06.041. Epub 2014 Jul 8.

PMID:
25010833
9.

Osteoporosis caused by mutations in PLS3: clinical and bone tissue characteristics.

Fahiminiya S, Majewski J, Al-Jallad H, Moffatt P, Mort J, Glorieux FH, Roschger P, Klaushofer K, Rauch F.

J Bone Miner Res. 2014 Aug;29(8):1805-14. doi: 10.1002/jbmr.2208.

10.

Factor XIIIA transglutaminase expression and secretion by osteoblasts is regulated by extracellular matrix collagen and the MAP kinase signaling pathway.

Piercy-Kotb SA, Mousa A, Al-Jallad HF, Myneni VD, Chicatun F, Nazhat SN, Kaartinen MT.

J Cell Physiol. 2012 Jul;227(7):2936-46. doi: 10.1002/jcp.23040.

PMID:
21959563
11.

Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics.

Al-Jallad HF, Myneni VD, Piercy-Kotb SA, Chabot N, Mulani A, Keillor JW, Kaartinen MT.

PLoS One. 2011 Jan 20;6(1):e15893. doi: 10.1371/journal.pone.0015893.

12.

Expression and localization of plasma transglutaminase factor XIIIA in bone.

Nakano Y, Al-Jallad HF, Mousa A, Kaartinen MT.

J Histochem Cytochem. 2007 Jul;55(7):675-85. Epub 2007 Mar 6.

PMID:
17341477
13.

Transglutaminase activity regulates osteoblast differentiation and matrix mineralization in MC3T3-E1 osteoblast cultures.

Al-Jallad HF, Nakano Y, Chen JL, McMillan E, Lefebvre C, Kaartinen MT.

Matrix Biol. 2006 Apr;25(3):135-48. Epub 2006 Feb 15.

PMID:
16469487

Supplemental Content

Loading ...
Support Center